PregLem is a Swiss-based specialty biopharmaceutical company dedicated to the development and commercialisation of innovative drugs for women’s reproductive medicine. The company was founded in June 2006 by Ernest Loumaye, a specialist in female reproductive medicine, and Eric Rolin, a finance executive in the pharmaceutical industry. PregLem’s team is skilled in Pre-Clinical and Clinical Product Development, CMC, Regulatory Affairs, Sales and Marketing and Corporate Finance.
On 7th October 2010, Gedeon Richter Plc. announced the acquisition of PregLem SA and PregLem became a member of the Richter Group.
PregLem’s product pipeline focuses on women’s reproductive medicine with significant unmet medical needs that severely impact a patient’s quality of life and fertility:
PregLem has in-licensed several products, which are at clinical and pre-clinical stages of development, from Ipsen Pharma (France) (PGL1001 & PGL2001), HRA Pharma (France) (ESMYA®/ Ulipristal Acetate/PGL4001) and Merck Serono (PGL5001). The company, together with Gedeon Richter, is actively seeking additional partnerships and in-licensing opportunities.
The company is supported by a Scientific Advisory Board comprising the Heads of Reproductive Medicine Departments from major European academic institutions.